Spreadsheet: 09a5a775-de7e-4e46-940e-d1aa7f6884e4
Sheet: Sheet1

Supplemental Table· Analytical description of the 160 meta-analyses with observed and expected numbers of "positive" study datasets
Disease | Outcome | Intervention/Treatment | Studies | Comparisons | Cases/controls | Fixed effects† | Random effects* | Most precise study effect‡ | I2 (95% CI) [P] | Egger§ | O¶ | E (fixed)# | P (fixed)** | E (random)†† | P (random)** | E (precise)‡‡ | P (precise)**
Alzheimer's | Morris water maze | Various | 82 | 250 | 2652/2766 | 0·55 (0·48, 0·62) | 0·76 (0·63, 0·89) | 0·51 (-0·004· 1·03) | 68 (64-72) [<0·01] | <0·01 | 76 | 51·3 | <0·01 | [NAME] | NP | 45·8 | <0·01
Alzheimer's | Plaque area | Various | 318 | 804 | 6152/6127 | 0·85 (0·80, 0·89) | 1·11 (1·01, 1·20) | [-0·04 (-0·52, 0·44)] | 71 (69-73) [<0·01] | <0·01 | 342 | 226 | <0·01 | 331 | 0·43 | 40·6 | <0·01
EAE | Mean severity | Aminoguanidine | 4 | 9 | 70/82 | 0·40 (0·04, 0·77) | 0·45 (-0·22, 1·12) | 1·10 (0·19, 2·01) | 70 (26-83) [<0·01] | 0·59 | 2 | 1·01 | 0·27 | 1·15 | 0·32 | 4·29 | NP
EAE | Mean severity | Azathioprine | 1 | 3 | 31/39 | 0·59 (-0·10, 1·28) | [NAME] (-0·28, 1·54) | [-0·15 (-1·23, 0·93)] | 41 (0-83) [0·18] | 0·38 | 1 | 0·72 | 0·56 | 0·8 | 0·99 | 0·19 | 0·17
EAE | Mean severity | Bone Marrow | 2 | 24 | 269/279 | 1·06 (0·78, 1·35) | 1·62 (1·04, 2·21) | 0 (-0·92, 0·92) | 75 (61-82) [<0·01] | <0·01 | 15 | 14·5 | 0·99 | 22·5 | NP | 1·2 | <0·01
EAE | Mean severity | Cobra Venom Factor | 2 | 8 | 76/79 | 1·02 (0·58, 1·46) | 1·09 ([NAME], 1·66) | 0·46 (-0·53, 1·44) | 38 (0-71) [0·12] | 0·02 | 4 | 3·95 | 0·99 | 4·36 | NP | 1·17 | 0·02
EAE | Mean severity | Complete Freunds Adjuvant | 3 | 6 | 44/42 | 1·61 (0·79, 2·43) | 1·85 (-0·09, 3·78) | 2·79 (1·27, 4·31) | 81 (51-90) [<0·01] | 0·57 | 2 | 3·99 | NP | 4·81 | NP | 6 | NP
EAE | Mean severity | Cyclophosphamide | 3 | 10 | 205/411 | [-0·09 (-0·30, 0·11)] | 0·17 (-0·48, 0·83) | [-0·32 (-0·64, 0·01)] | 85 (74-90) [<0·01] | 0·17 | 3 | 0·62 | 0·02 | 0·92 | 0·06 | 1·86 | 0·41
EAE | Mean severity | Cyclosporin | 8 | 14 | 161/184 | 0·72 (0·41, 1·02) | 0·93 (0·30, 1·55) | 0·56 (-0·06, 1·18) | 72 (48-83) [<0·01] | <0·01 | 6 | 4·43 | 0·39 | 6·35 | NP | 3·05 | 0·10
EAE | Mean severity | Dexamethasone | 4 | 4 | 25/52 | 0·55 (-0·08, 1·19) | 0·55 (-0·08, 1·19) | 0·28 (-0·82, 1·38) | 0 (0-68) [0·76] | 0·03 | 0 | 0·63 | NP | 0·63 | NP | 0·31 | NP
EAE | Mean severity | [NAME] | 7 | 42 | 415/531 | 1·10 (0·91, 1·29) | 1·49 (1·08, 1·90) | 0·84 (0·32, 1·36) | 74 (64-80) [<0·01] | <0·01 | 22 | 22·3 | NP | 29·8 | NP | 15·8 | 0·06
EAE | Mean severity | Fingolimod (FTY720) | 3 | 9 | 91/111 | 2·39 (1·75, 3·03) | 3·14 (1·29, 4·98) | 1·30 (0·07, 2·53) | 83 (67-89) [<0·01] | 0·05 | 7 | 8·89 | NP | 9 | NP | 6·23 | 0·73
EAE | Mean severity | Glatiramer Acetate | 9 | 20 | 250/249 | 1·02 (0·80, 1·25) | 1·56 (0·97, 2·16) | 0·34 (-0·23, 0·91) | 84 (77-89) [<0·01] | <0·01 | 13 | 11·5 | 0·65 | 17·8 | NP | 2·4 | <0·01
EAE | Mean severity | Immunoglobulin | 3 | 5 | 139/90 | 0·89 (0·56, 1·23) | 1·01 (0·22, 1·80) | 1·15 (0·67, 1·62) | 77 (17-89) [<0·01] | 0·71 | 3 | 3·49 | NP | 3·95 | NP | 4·37 | NP
EAE | Mean severity | Indomethacin | 2 | 3 | 30/22 | 0·91 (0·23, 1·60) | 1·06 (-0·01, 2·14) | 0·68 (-0·23, 1·59) | 52 (0-85) [0·12] | 0·45 | 1 | 1·08 | NP | 1·38 | NP | 0·67 | 0·53
EAE | Mean severity | Insulin Like Growth Factor | 1 | 4 | 38/38 | 4·85 (3·85, 5·85) | 5·00 (3·65, 6·34) | 4·04 (2·29, 5·80) | 43 (0-80) [0·15] | <0·01 | 4 | 4 | 0·99 | 4 | 0·99 | 4 | 0·99
EAE | Mean severity | Interferon Beta | 6 | 9 | 71/71 | [NAME] (-0·24, 0·61) | 0·42 (-0·67, 1·52) | [-0·69 (-1·53, 0·15)] | 84 (69-90) [<0·01] | 0·28 | 4 | 0·56 | <0·01 | 1·04 | 0·01 | 1·95 | 0·11
EAE | Mean severity | Interleukin 10 | 7 | 34 | 294/313 | [-0·18 (-0·38, 0·02)] | [-0·18 (-0·56, 0·19)] | 0·46 (-0·26, 1·19) | 70 (55-78) [<0·01] | 0·98 | 9 | 2·15 | <0·01 | 2·16 | <0·01 | 4·60 | 0·04
EAE | Mean severity | Interleukin 4 | 3 | 10 | 67/148 | 0·49 (0·10, 0·88) | 0·49 (0·10, 0·88) | 0·07 (-0·82, 0·97) | 0 (0-53) [0·52] | <0·01 | 2 | 1·51 | 0·65 | 1·51 | 0·65 | 0·52 | 0·09
EAE | Mean severity | Linomide | 2 | 4 | 68/84 | 2·91 (1·89, 3·93) | 14·5 (4·53, 24·5) | 0·62 (-0·82, 2·06) | 99 (98-99) [<0·01] | 0·05 | 2 | 4 | NP | 4 | NP | 1·49 | 0·63
EAE | Mean severity | [NAME] | 2 | 7 | 62/87 | 1·19 (0·71, 1·66) | 1·36 (0·64, 2·08) | [NAME] (-0·47, 1·29) | 54 (0-78) [0·04] | 0·01 | 4 | 4·59 | NP | 5·39 | NP | 0·93 | <0·01
EAE | Mean severity | [NAME] | 33 | 148 | 1138/1638 | 0·75 (0·65, 0·86) | 0·98 (0·77, 1·19) | 0·82 (0·32, 1·32) | 67 (60-72) [<0·01] | <0·01 | 47 | 38·7 | 0·13 | 55·5 | NP | 43·4 | 0·53
EAE | Mean severity | Methotrexate | 1 | 2 | 16/20 | 0·74 (-0·41, 1·88) | 0·93 (-1·80, 3·67) | [-0·42 (-1·92, 1·08) | 82 (ΝΑ) [0·02] | ΝΑ | 1 | 0·53 | 0·46 | 0·78 | 0·99 | 0·24 | 0·23
EAE | Mean severity | Methylprednisolone | 4 | 10 | 182/180 | [-0·15 (-0·49, 0·20)] | [-0·14 (-1·15, 0·86)] | 0·54 (-0·36, 1·45) | 88 (80-92) [<0·01] | 0·99 | 6 | 0·69 | <0·01 | 0·69 | <0·01 | 3·15 | 0·08
EAE | Mean severity | Minocycline | 2 | 3 | 22/25 | 1·68 (0·91, 2·45) | 1·72 (0·48, 2·97) | 2·16 (0·90, 3·43) | 61 (0-87) [0·07] | 0·63 | 2 | 2·49 | NP | 2·56 | NP | 2·95 | NP
EAE | Mean severity | Mitoxantrone | 4 | 30 | 224/398 | 1·65 (1·34, 1·95) | 2·18 (1·56, 2·80) | 0·53 (-0·52, 1·59) | 73 (61-81) [<0·01] | <0·01 | 20 | 25·4 | NP | 29·1 | NP | 5·29 | <0·01
EAE | Mean severity | [NAME] | 2 | 7 | 80/71 | [-0·07 (-0·44, 0·31)] | [-0·05 (-0·58, 0·48)] | 0·26 (-0·63, 1·14) | 48 (0-76) [0·07] | 0·66 | 1 | 0·37 | 0·31 | 0·36 | 0·31 | 0·59 | 0·46
EAE | Mean severity | Phenytoin | 2 | 2 | 11/11 | 3·15 (1·70, 4·59) | 3·15 (1·70, 4·59) | 2·59 (0·68, 4·51) | 0 (ΝΑ) [0·39] | ΝΑ | 2 | 2 | 0·99 | 2 | 0·99 | 1·94 | 0·99
EAE | Mean severity | Proteolipid Protein | 2 | 2 | 19/28 | [-0·97 (-1·62, -0·32)] | [-0·92 (-1·78, -0·05)] | [-1·27 (-2·07, -0·48)] | 38 (ΝΑ) [0·20] | ΝΑ | 1 | 0·98 | 0·99 | [NAME] | 0·99 | 1·36 | NP
EAE | Mean severity | Prednisolone | 3 | 3 | 17/17 | 1·54 (0·64, 2·44) | 1·54 (0·64, 2·44) | 1·55 (0·12, 2·98) | 0 (0-73) [0·56] | 0·48 | 2 | 1·61 | 0·99 | 1·61 | 0·99 | 1·62 | 0·99
EAE | Mean severity | Reserpine | 1 | 5 | 23/35 | 1·61 (0·06, 3·15) | 2·72 (-0·22, 5·66) | 0·99 (-0·94, 2·92) | 47 (0-79) [0·11] | 0·12 | 1 | 2·61 | NP | 4·63 | NP | 1·26 | NP
EAE | Mean severity | Rolipram | 3 | 9 | 117/109 | 0·69 ([NAME], 0·97) | [NAME] (0·06, 1·19) | 0·56 (0·03, 1·08) | 73 (36-84) [<0·01] | 0·61 | 7 | 2·99 | <0·01 | 2·58 | <0·01 | 2·16 | <0·01
EAE | Mean severity | [NAME] | 2 | 5 | 32/32 | 0·26 (-0·46, 0·98) | 0·99 (-0·50, 2·48) | [-0·22 (-1·16, 0·71)] | 65 (0-85) [0·02] | 0·04 | 2 | 0·34 | 0·04 | 1·51 | 0·64 | 0·32 | 0·04
EAE | Mean severity | Transforming Growth Factor | 4 | 8 | 69/124 | 0·22 (-0·17, 0·62) | 0·28 (-0·28, 0·84) | 0·19 (-0·54, 0·92) | 45 (0-74) [0·08] | 0·52 | 1 | 0·61 | 0·47 | 0·72 | 0·53 | 0·55 | 0·43
EAE | Mean severity | [NAME] 8 | 5 | 11 | 52/62 | 1·46 (0·87, 2·05) | 2·12 (0·84, 3·39) | 1·29 (-0·15, 2·73) | 76 (52-85) [<0·01] | 0·01 | 6 | 4·31 | 0·36 | 6·65 | NP | 3·64 | 0·20
EAE | Mean severity | Vitamin D | 6 | 13 | 196/271 | 1·16 (0·93, 1·40) | 1·48 (0·85, 2·12) | 0·33 (-0·21, 0·86) | 84 (74-89) [<0·01] | 0·12 | 9 | 9·19 | NP | 10·3 | NP | 1·88 | <0·01
Focal | Infarct volume | Hypothermia | 107 | 221 | 1803/1949 | 1·39 (1·30, 1·48) | 1·69 (1·53, 1·86) | 1·08 (0·42, 1·74) | 68 (63-72) [<0·01] | <0·01 | 135 | 145 | NP | 180 | NP | 101 | <0·01
Focal | Infarct volume | Stem Cells | 110 | 211 | 1611/1657 | 0·81 (0·71, 0·91) | 1·21 (1·00, 1·41) | 0·91 (0·20, 1·62) | 73 (69-76) [<0·01] | <0·01 | 84 | 63·7 | <0·01 | 102 | NP | 67·6 | 0·02
Focal | Infarct volume | Thrombolytic | 83 | 202 | 1949/1996 | 0·58 (0·51, 0·66) | 0·67 (0·56, 0·78) | [-0·04 (-0·59, 0·52)] | 48 (38-56) [<0·01] | <0·01 | 60 | 41·1 | <0·01 | 50·3 | 0·12 | 10·2 | <0·01
Focal | Infarct volume | Anti-oxidants | 18 | 34 | 309/309 | 0·92 (0·72, 1·12) | 1·18 (0·78, 1·59) | 0·57 (-0·08, 1·22) | 74 (62-80) [<0·01] | <0·01 | 14 | 13·2 | 0·86 | 19·4 | NP | 6·31 | <0·01
Focal | Infarct volume | Growth factor | 78 | 128 | 981/1026 | 0·93 (0·82, 1·04) | 1·09 ([NAME], 1·27) | 0·78 (0·14, 1·42) | 60 (51-67) [<0·01] | <0·01 | 53 | 42·7 | 0·06 | 54·3 | NP | 32·7 | <0·01
Focal | Infarct volume | Nootropic | 5 | 14 | 120/128 | 0·93 (0·60, 1·26) | 0·97 (0·53, 1·42) | 1·44 (0·43, 2·44) | 42 (0-68) [0·05] | 0·05 | 7 | 5·38 | 0·42 | 5·76 | 0·59 | 9·70 | NP
Focal | Infarct volume | Anti-inflammatory | 23 | 44 | 396/550 | 0·99 (0·84, 1·15) | 1·10 (0·88, 1·31) | [-0·09 (-0·85, 0·67)] | 44 (15-60) [<0·01] | <0·01 | 31 | 20 | <0·01 | 23 | 0·02 | 2·36 | <0·01
Focal | Infarct volume | Estrogens | 33 | 100 | 847/905 | 0·72 (0·60, 0·84) | [NAME] (0·68, 1·12) | 0·37 (-0·35, 1·08) | 68 (61-74) [<0·01] | <0·01 | 46 | 25·6 | <0·01 | 36 | 0·05 | 10·4 | <0·01
Focal | Infarct volume | Minocycline | 8 | 25 | 335/337 | 0·84 (0·65, 1·03) | 0·83 (0·60, 1·07) | 1·20 (0·55, 1·84) | 28 (0-55) [0·10] | 0·85 | 11 | 11·4 | NP | 11·3 | NP | 17 | NP
Focal | Infarct volume | Melatonin | 12 | 29 | 276/303 | 1·13 (0·90, 1·35) | 1·13 (0·90, 1·35) | 1·33 (0·51, 2·14) | 0 (0-37) [0·87] | 0·47 | 9 | 16·5 | NP | 16·5 | NP | 20·3 | NP
Focal | Infarct volume | Urokinase | 12 | 26 | 247/233 | 0·91 (0·66, 1·16) | 1·86 (1·22, 2·50) | [-0·29 (-1·01, 0·43)] | 83 (76-87) [<0·01] | <0·01 | 18 | 10·1 | <0·01 | 23·6 | NP | 2·26 | <0·01
Focal | Infarct volume | Nicotinamide | 11 | 57 | 458/538 | 0·87 (0·69, 1·04) | 0·89 (0·70, 1·08) | 0·56 (-0·03, 1·15) | 11 (0-36) [0·25] | 0·16 | 10 | 19 | NP | 19·8 | NP | 9·86 | 0·99
Focal | Infarct volume | Disufenton sodium (NXY-059) | 10 | 29 | 249/250 | 0·94 (0·70, 1·18) | 1·40 (0·97, 1·83) | 0·09 (-0·52, 0·69) | 64 (43-75) [<0·01] | <0·01 | 14 | 11·1 | 0·26 | 19·7 | NP | 1·54 | <0·01
Focal | Infarct volume | Nitric Oxide Species Inhibitors | 65 | 148 | 1201/1415 | 0·67 (0·56, 0·77) | 0·80 (0·61, 0·98) | 0·69 (-0·08, 1·46) | 66 (59-71) [<0·01] | <0·01 | 63 | 33 | <0·01 | 43·3 | <0·01 | 34·6 | <0·01
Focal | Infarct volume | Nitric Oxide Species Donors | 20 | 40 | 280/356 | 0·71 (0·50, 0·92) | 0·76 (0·44, 1·08) | 1·58 (0·76, 2·41) | 53 (29-67) [<0·01] | 0·17 | 16 | 8·71 | 0·01 | 9·78 | 0·03 | 28·2 | NP
Focal | Infarct volume | Tacrolimus (FK506) | 29 | 95 | 921/947 | 1·07 (0·95, 1·19) | 1·26 (1·07, 1·45) | 0·50 (-0·20, 1·21) | 57 (45-66) [<0·01] | <0·01 | 55 | 50·3 | 0·36 | 62·9 | NP | 15·8 | <0·01
ICH | Neurobehavioural score | Propofol | 1 | 3 | 30/30 | 1·97 (1·05, 2·89) | 2·18 (0·74, 3·62) | 1·26 (-0·10, 2·63) | 56 (0-86) [0·10] | 0·05 | 2 | 2·98 | NP | 3 | NP | 2·14 | NP
ICH | Neurobehavioural score | Tauroursodeoxycholic acid | 1 | 9 | 45/45 | 1·12 (0·64, 1·60) | 1·12 (0·64, 1·60) | 0·51 (-0·76, 1·78) | 0 (0-54) [0·60] | <0·01 | 2 | 2·5 | NP | 2·5 | NP | 0·91 | 0·23
ICH | Neurobehavioural score | Minocycline | 3 | 9 | 93/96 | [-0·05 (-0·41, 0·30)] | 0·07 (-0·54, 0·69) | 0·03 (-0·91, 0·97) | 65 (8-81) [<0·01] | 0·06 | 3 | 0·46 | <0·01 | 0·47 | <0·01 | 0·45 | <0·01
ICH | Neurobehavioural score | Anti-inflammatory | 7 | 26 | 218/214 | 1·19 (0·89, 1·48) | 2·06 (1·34, 2·77) | 0·79 (0·10, 1·48) | 79 (68-84) [<0·01] | <0·01 | 15 | 13·6 | 0·70 | 24·1 | NP | 7·32 | <0·01
ICH | Neurobehavioural score | Anti-oxidants | 9 | 32 | 310/341 | [-0·17 (-0·37, 0·03)] | [-0·04 (-0·44, 0·36)] | 0 (-0·67, 0·67) | 66 (48-76) [<0·01] | 0·02 | 12 | 2·03 | <0·01 | 1·62 | <0·01 | 1·6 | <0·01
ICH | Neurobehavioural score | Afobazol | 1 | 4 | 20/20 | 1·32 (0·39, 2·26) | 1·32 (0·39, 2·26) | 0·60 (-0·98, 2·18) | 0 (0-68) [0·59] | 0·01 | 1 | 1·44 | NP | 1·44 | NP | 0·48 | 0·4
ICH | Neurobehavioural score | Calcium channel blockers | 5 | 7 | 108/108 | 0·72 (0·42, 1·02) | 0·47 (-0·04, 0·98) | 1·06 (0·64, 1·48) | 52 (0-78) [0·05] | 0·02 | 2 | 2·64 | NP | 1·52 | 0·65 | 4·14 | NP
ICH | Neurobehavioural score | Chinese traditional medicine | 2 | 2 | 10/10 | 0·76 (-0·17, 1·69) | 0·76 (-0·17, 1·69) | 0·59 (-0·70, 1·87) | 0 (NA) [0·70] | NA | 0 | 0·32 | NP | 0·32 | NP | 0·23 | NP
ICH | Neurobehavioural score | Ganaloxone | 1 | 4 | 36/44 | [-0·42 (-0·88, 0·04)] | [-0·49 (-1·26, 0·28)] | 0 (-0·88, 0·88) | 64 (0-86) [0·04] | 0·02 | 1 | 0·53 | 0·43 | 0·64 | 0·5 | 0·2 | 0·19
ICH | Neurobehavioural score | Carbenoxolone | 1 | 12 | 72/78 | [-0·57 (-0·91, -0·23)] | [-0·57 (-0·91, -0·23)] | 0·14 (-1·00, 1·27) | 0 (0-50) [0·45] | <0·01 | 2 | 1·63 | 0·67 | 1·63 | 0·67 | 0·66 | 0·14
ICH | Neurobehavioural score | Glutamate receptor antagonists | 4 | 6 | 53/63 | 0·58 (0·08, 1·09) | 1·62 (-0·01, 3·25) | 0·33 (-0·75, 1·41) | 89 (79-93) [<0·01] | <0·01 | 1 | 1·2 | NP | 5·07 | NP | 0·59 | 0·46
ICH | Neurobehavioural score | Growth factor | 3 | 5 | 70/70 | 5·35 (4·55, 6·15) | 6·37 (4·18, 8·55) | 4·03 (2·73, 5·34) | 85 (61-92) [<0·01] | <0·01 | 5 | 5 | 0·99 | 5 | 0·99 | 5 | 0·99
ICH | Neurobehavioural score | Zinc protoporphyrin | 1 | 2 | 16/16 | 0·37 (-0·34, 1·08) | 0·38 (-0·52, 1·28) | [-0·07 (-1·05, 0·91)] | 37 (NA) [0·21] | NA | 0 | 0·2 | NP | 0·2 | NP | 0·1 | NP
ICH | Neurobehavioural score | Atorvastatin | 2 | 6 | 50/50 | 1·11 (0·51, 1·71) | 2·15 (0·26, 4·04) | 0·08 (-1·12, 1·28) | 88 (75-93) [<0·01] | <0·01 | 3 | 2·97 | 0·99 | 5·95 | NP | 0·31 | <0·01
ICH | Neurobehavioural score | Hypothermia | 6 | 33 | 491/541 | [[NAME] (-0·18, 0·14)] | 0·003 (-0·19, 0·19) | 0·06 (-0·68, 0·81) | 27 (0-52) [0·08] | <0·01 | 2 | 1·66 | 0·68 | 1·65 | 0·68 | 1·75 | 0·69
ICH | Neurobehavioural score | Tacrolimus (FK506) | 1 | 3 | 30/30 | 0·51 ([NAME], 1·04) | 0·57 (-0·38, 1·51) | [-0·21 (-1·09, 0·67)] | 68 (0-89) [0·04] | 0·23 | 1 | 0·52 | 0·44 | 0·61 | 0·49 | 0·21 | 0·2
ICH | Neurobehavioural score | Iron chelator | 6 | 14 | 99/106 | 1·16 (0·81, 1·51) | 1·37 (0·81, 1·93) | 0·52 (-0·49, 1·53) | 57 (8-75) [<0·01] | <0·01 | 7 | 6·35 | 0·79 | 8·14 | NP | 1·9 | <0·01
ICH | Neurobehavioural score | Galardin (GM-6001) | 1 | 3 | 51/54 | 0·33 (-0·21, 0·88) | 0·34 (-0·35, 1·03) | [-0·24 (-1·18, 0·69)] | 36 (0-82) [0·21] | 0·28 | 1 | 0·45 | 0·39 | 0·47 | 0·4 | 0·31 | 0·28
ICH | Neurobehavioural score | Tuftsin fragment 1-3 | 1 | 2 | 29/26 | 1·21 (0·62, 1·79) | 1·21 (0·62, 1·79) | 1·33 (0·59, 2·08) | 0 (NA) [0·59] | NA | 2 | 1·6 | 0·99 | 1·6 | 0·99 | 1·73 | 0·99
ICH | Neurobehavioural score | Cerebral | 1 | 3 | 21/21 | 0·96 (0·23, 1·69) | 1·52 (-0·37, 3·40) | 0 (-1·05· 1·05) | 83 (0-93) [<0·01] | 0·17 | 1 | 0·97 | 0·99 | 2·01 | NP | 0·15 | 0·14
ICH | Neurobehavioural score | 17b [NAME] | 3 | 13 | 161/179 | 0·16 (-0·09, 0·41) | 0·16 (-0·09, 0·41) | 0·007 (-0·74, 0·76) | 0 (0-49) [0·66] | 0·01 | 1 | 0·86 | 0·59 | 0·86 | 0·59 | 0·65 | 0·49
ICH | Neurobehavioural score | PPAR-gamma agonist | 2 | 3 | 37/37 | 3·36 (2·52, 4·20) | 5·38 (1·82, 8·95) | 2·00 (0·94, 3·06) | 92 (79-96) [<0·01] | 0·18 | 3 | 3 | 0·99 | 3 | 0·99 | 3 | 0·99
ICH | Neurobehavioural score | Psychomotor stimulant | 3 | 7 | 98/104 | 0·17 (-0·15, 0·48) | [-0·36 (-1·19, 0·48)] | 0·76 (0·27, 1·25) | 82 (60-90) [<0·01] | 0·03 | 3 | 0·49 | <0·01 | 1 | 0·06 | 2·98 | 0·99
ICH | Neurobehavioural score | Protein Phosphatase 1 | 1 | 2 | 18/28 | 0·80 (0·06, 1·55) | 0·80 (0·06, 1·55) | 0·48 (-0·52, 1·49) | 0 (NA) [0·35] | NA | 1 | 0·78 | 0·99 | 0·78 | 0·99 | 0·35 | 0·32
ICH | Neurobehavioural score | Stem Cells | 14 | 37 | 408/371 | 1·64 (1·45, 1·84) | 1·77 (1·38, 2·15) | 2·81 (2·09, 3·53) | 71 ( 58-78) [<0·01] | 0·08 | 25 | 30·9 | NP | 32·5 | NP | 36·9 | NP
ICH | Neurobehavioural score | Thrombin inhibitor | 3 | 7 | 56/50 | 0·60 (0·12, 1·08) | 0·60 (0·12, 1·08) | 0·02 (-1·04, 1·08) | 0 (0-58) [0·54] | <0·01 | 0 | 1·19 | NP | 1·19 | NP | 0·35 | NP
ICH | Neurobehavioural score | Cystamine | 1 | 3 | 18/18 | [NAME] (-0·04, 1·31) | [NAME] (-0·04, 1·31) | 0·37 (-0·78, 1·52) | 0 (0-73) [0·85] | 0·03 | 0 | 0·42 | NP | 0·42 | NP | 0·25 | NP
ICH | Neurobehavioural score | ORF4-PE | 1 | 3 | 18/18 | 1·31 (0·44, 2·18) | 1·31 (0·44, 2·18) | 1·09 (-0·16, 2·34) | 0 (0-73) [0·46] | 0·31 | 1 | 1·34 | NP | 1·34 | NP | 0·99 | 0·99
ICH | Neurobehavioural score | [NAME] | 1 | 6 | 48/48 | 0·78 (0·26, 1·31) | 0·78 (0·26, 1·31) | 1·03 (-0·03, 2·09) | 0 (0-61) [0·90] | 0·86 | 0 | 1·62 | NP | 1·62 | NP | 2·51 | NP
ICH | Brain water content | Propofol | 1 | 3 | 18/18 | 1·42 (0·32, 2·52) | 1·42 (0·32, 2·52) | 0·80 (-0·89, 2·50) | 0 (0-73) [0·64] | 0·02 | 0 | 1·53 | NP | 1·53 | NP | 0·63 | NP
ICH | Brain water content | Minocycline | 1 | 2 | 12/12 | 2·62 (1·41, 3·84) | 2·62 (1·41, 3·84) | 2·33 (0·73, 3·94) | 0 (NA) [0·59] | NA | 2 | 1·99 | 0·99 | 1·02 | 0·5 | 1·92 | 0·99
ICH | Brain water content | Anti-inflammatory | 7 | 13 | 105/107 | 0·85 (0·48, 1·22) | 1·18 (0·50, 1·86) | 0·28 (-0·54, 1·11) | 66 (29-80) [<0·01] | 0·02 | 4 | 4·05 | NP | 6·7 | NP | 1·04 | 0·02
ICH | Brain water content | Anti-oxidants | 5 | 29 | 174/183 | 0·30 (-0·03, [NAME]) | 0·60 (-0·05, 1·25) | [-0·47 (-1·61, 0·67)] | 70 (54-78) [<0·01] | 0·04 | 9 | 2·15 | <0·01 | 4·15 | 0·03 | 3·12 | <0·01
ICH | Brain water content | Calcium channel blockers | 2 | 4 | 30/30 | 0·49 (-0·19, 1·17) | 0·49 (-0·19, 1·17) | 1·21 (-0·07, 2·48) | 0 (0-68) [0·58] | 0·13 | 0 | 0·52 | NP | 0·52 | NP | 2·01 | NP
ICH | Brain water content | Garbenoxolone | 1 | 8 | 48/52 | 0·45 (-0·04, 0·94) | 0·45 (-0·04, 0·94) | 0·36 (-0·98, 1·69) | 0 (0-56) [0·98] | 0·26 | 0 | 0·83 | NP | 0·83 | NP | 0·67 | NP
ICH | Brain water content | Glutamate receptor antagonists | 3 | 4 | 36/38 | [-0·20 (-0·71, 0·31)] | [-0·20 (-0·71, 0·31)] | [-0·31 (-1·12, 0·50)] | 0 (0-68) [0·76] | 0·98 | 0 | 0·27 | NP | 0·27 | NP | 0·37 | NP
ICH | Brain water content | Growth factor | 2 | 2 | 18/18 | 4·98 (3·51, 6·45) | 4·95 (3·19, 6·70) | 5·76 (3·81, 7·71) | 29 (NA) [0·23] | NA | 2 | 2 | 0·99 | 2 | 0·99 | 2 | 0·99
ICH | Brain water content | Zinc protoporphyrin | 1 | 2 | 12/12 | 1·40 (0·46, 2·34) | 1·40 (0·46, 2·34) | 1·31 (0·01, 2·60) | 0 (NA) [0·83] | NA | 2 | 0·99 | 0·25 | 0·99 | 0·25 | 0·89 | 0·20
ICH | Brain water content | Recombinant Factor VIIa | 1 | 2 | 12/12 | 0·24 (-0·57, 1·05) | 0·24 (-0·57, 1·05) | 0 (-1·13, 1·13) | 0 (NA) [0·56] | NA | 0 | 0·13 | NP | 0·13 | NP | 0·1 | NP
ICH | Brain water content | Geranyl geranyl acetone | 1 | 3 | 18/18 | 1·35 (0·23, 2·46) | 1·35 (0·23, 2·46) | 0·84 (-0·86, 2·55) | 0 (0-73) [0·37] | 0·04 | 1 | 1·4 | NP | 1·4 | NP | 0·67 | 0·53
ICH | Brain water content | Atorvastatin | 1 | 2 | 18/18 | 3·77 (2·28, 5·26) | 4·12 (1·53, 6·71) | 3·01 (1·25, 4·77) | 60 (NA) [0·11] | NA | 2 | 2 | 0·99 | 2 | 0·99 | 2 | 0·99
ICH | Brain water content | Hypothermia | 3 | 5 | 37/39 | 0·86 (0·32, 1·40) | 0·86 (0·32, 1·40) | 0·22 (-0·86, 1·30) | 0 (0-64) [0·53] | 0·07 | 1 | 1·48 | NP | 1·48 | NP | 0·33 | 0·29
ICH | Brain water content | Deferoxamine | 2 | 12 | 90/120 | 1·07 (0·70, 1·44) | 1·08 (0·69, 1·47) | 0·31 (-0·83, 1·45) | 10 (0-55) [0·34] | <0·01 | 6 | 5·58 | 0·99 | 5·7 | 0·99 | 1·05 | <0·01
ICH | Brain water content | Tuftsin fragment | 1 | 2 | 10/10 | 1·83 (0·69, 2·98) | 1·83 (0·69, 2·98) | 1·63 (0·09, 3·17) | 0 (NA) [0·69] | NA | 2 | 1·21 | 0·52 | 1·21 | 0·52 | 1 | 0·25
ICH | Brain water content | [NAME] | 2 | 4 | 24/24 | 0·94 (0·28, 1·61) | 1·38 (0·13, 2·62) | 0·29 (-0·64, 1·22) | 65 (0-86) [0·03] | 0·02 | 2 | 1·06 | 0·29 | 1·88 | 0·99 | 0·28 | 0·03
ICH | Brain water content | Stem cells | 2 | 5 | 32/32 | 1·43 (0·64, 2·22) | 1·43 (0·64, 2·22) | 1·60 (0·43, 2·77) | 0 (0-64) [0·49] | 0·47 | 2 | 2·76 | NP | 2·76 | NP | 3·27 | NP
ICH | Brain water content | Batroxobin | 1 | 3 | 18/18 | 0·50 (-0·45, 1·45) | 0·50 (-0·45, 1·45) | 0·18 (-1·42, 1·79) | 0 (0-73) [0·89] | 0·04 | 0 | 0·34 | NP | 0·34 | NP | 0·18 | NP
ICH | Brain water content | Cystamine | 1 | 2 | 12/12 | 1·02 (0·12, 1·93) | 1·08 (-0·14, 2·31) | [NAME] (-0·64, 1·68) | 44 (NA) [0·18] | NA | 1 | 0·6 | 0·51 | 0·65 | 0·55 | 0·24 | 0·22
ICH | Hematoma volume | Tauroursodeoxycho | 1 | 3 | 12/12 | 1·21 (0·14, 2·29) | 1·80 (-0·43, 4·03) | 0·98 (-0·56, 2·52) | 67 (0-88) [0·05] | <0·01 | 1 | 1·18 | NP | 1·24 | NP | 0·52 | 0·44
ICH | Hematoma volume | Anti-inflammatory | 5 | 8 | 53/56 | [NAME]) | 0·60 (-0·07, 1·28) | 0·02 (-0·78, 0·82) | 46 (0-74) [0·08] | 0·06 | 2 | 0·84 | 0·2 | 1·26 | 0·37 | 0·4 | 0·06
ICH | Hematoma volume | Anti-oxidants | 3 | 5 | 36/34 | 0·06 (-0·50, 0·62) | 0·06 (-0·50, 0·62) | 0·15 (-0·83, 1·14) | 0 (0-64) [0·46] | 0·58 | 0 | 0·26 | NP | 0·26 | NP | 0·29 | NP
ICH | Hematoma volume | Calcium channel blockers | 2 | 4 | 31/30 | 0·08 (-0·58, 0·74) | 0·08 (-0·58, 0·74) | 0·80 (-0·35, 1·96) | 0 (0-68) [0·50] | 0·02 | 0 | 0·21 | NP | 0·21 | NP | 1·06 | NP
ICH | Hematoma volume | Glutamate receptor antagonists | 2 | 5 | 41/44 | 0·29 (-0·23, 0·82) | 0·32 (-0·30, 0·95) | [-0·14 (-1·21, 0·94)] | 30 (0-74) [0·22] | 0·07 | 1 | 0·42 | 0·35 | 0·45 | 0·38 | 0·28 | 0·25
ICH | Hematoma volume | Growth factor | 2 | 3 | 18/18 | 0·51 (-0·23, 1·25) | 0·49 (-0·53, 1·51) | 0·48 (-0·68, 1·64) | 46 (0-84) [0·16] | 0·81 | 1 | 0·34 | 0·31 | 0·33 | 0·3 | 0·32 | 0·29
ICH | Hematoma volume | Recombinant Factor VIIa | 1 | 2 | 12/12 | [-2·03 (-3·11, -0·96)] | [-2·03 (-3·11, -0·96)] | [-1·74 (-3·15, -0·32)] | 0 (NA) [0·52] | NA | 2 | 1·71 | 0·99 | 1·71 | 0·99 | 1·39 | 0·99
ICH | Hematoma volume | Hypothermia | 4 | 8 | 113/113 | [-0·05 (-0·41, 0·30)] | [-0·05 (-0·41, 0·30)] | 0·05 (-0·82, 0·92) | 0 (0-56) [0·85] | 0·95 | 0 | 0·42 | NP | 0·42 | NP | 0·41 | NP
ICH | Hematoma volume | Tuftsin fragment | 1 | 2 | 12/12 | 1·57 (0·59, 2·54) | 1·57 (0·59, 2·54) | 1·35 (0·15, 2·56) | 0 (NA) [0·55] | NA | 2 | 1·17 | 0·51 | 1·17 | 0·51 | 0·93 | 0·22
ICH | Hematoma volume | Albumin | 1 | 3 | 24/18 | 0·10 (-0·51, 0·72) | 0·10 (-0·51, 0·72) | 0·05 (-1·01, 1·11) | 0 (0-73) [0·98] | 0·08 | 0 | 0·16 | NP | 0·16 | NP | 0·15 | NP
ICH | Hematoma volume | Rosiglitazone | 1 | 2 | 11/11 | 3·01 (1·59, 4·44) | 3·03 (1·06, 5·01) | 2·05 (0·07, 4·02) | 48 (NA) [0·17] | NA | 2 | 1·91 | 0·99 | 1·92 | 0·99 | 1·45 | 0·99
ICH | Hematoma volume | Psychomotor stimulant | 2 | 2 | 48/49 | [-0·10 (-0·51, 0·31)] | [-0·37 (-1·65, 0·92)] | 0·25 (-0·23, 0·73) | 87 (NA) [<0·01] | NA | 1 | 0·13 | 0·12 | 0·45 | 0·4 | 0·26 | 0·25
ICH | Hematoma volume | Stem cells | 1 | 4 | 24/24 | 0·30 (-0·60, 1·21) | 0·30 (-0·60, 1·21) | 0·13 (-1·67, 1·92) | 0 (0-68) [0·99] | 0·01 | 0 | 0·29 | NP | 0·29 | NP | 0·22 | NP
Parkinson's | Various | PHNO | 15 | 41 | 226/226 | 1·23 (0·88, 1·59) | 1·23 (0·88, 1·59) | 0 (-1·20, 1·20) | 0 (0-33) [0·99] | <0·01 | 6 | 14·8 | NP | 14·8 | NP | 2·05 | 0·02
Parkinson's | Various | 7-OH-DPAT | 4 | 7 | 58/58 | 1·26 (0·71, 1·82) | 1·31 (0·67, 1·95) | [NAME] (-0·74, 1·56) | 22 (0-67) [0·26] | 0·02 | 4 | 4·12 | NP | 4·34 | NP | 0·8 | <0·01
Parkinson's | Rotational behavior | A68930 | 5 | 10 | 78/78 | 0·54 (0·16, 0·92) | 0·54 (0·16, 0·92) | 0·68 (-0·23, 1·59) | 0 (0-53) [0·88] | 0·60 | 0 | 1·54 | NP | 1·54 | NP | 2·12 | NP
Parkinson's | Various | A77636 | 5 | 27 | 108/108 | 1·50 (0·95, 2·05) | 1·50 (0·95, 2·05) | 0·96 (-0·58, 2·49) | 0 (0-38) [0·93] | <0·01 | 1 | 8·48 | NP | 8·48 | NP | 4·62 | NP
Parkinson's | Various | A86929 | 7 | 17 | 68/68 | 1·55 (0·76, 2·34) | 1·55 (0·76, 2·34) | 2·31 (0·20, 4·42) | 0 (0-45) [0·92] | <0·01 | 2 | 5·6 | NP | 5·6 | NP | 10·5 | NP
Parkinson's | Various | ABT-431 | 3 | 8 | 32/32 | 1·23 (0·11, 2·34) | 1·23 (0·11, 2·34) | 0·31 (-1·92, 2·54) | 0 (0-56) [0·77] | <0·01 | 0 | 1·9 | NP | 1·9 | NP | 0·51 | NP
Parkinson's | Various | Amantadine | 2 | 8 | 32/32 | [-1·35 (-2·49, -0·21)] | [-1·35 (-2·49, -0·21)] | 0·04 (-2·15, 2·24) | 0 (0-56) [0·80] | <0·01 | 0 | 2·17 | NP | 2·17 | NP | 0·4 | NP
Parkinson's | Rotational behavior | Aplindore | 4 | 7 | 105/105 | 1·73 (1·40, 2·06) | 1·88 (1·25, 2·51) | 0·78 (0·04, 1·53) | 71 (16-85) [<0·01] | <0·01 | 7 | 6·99 | 0·99 | 7 | 0·99 | 3·49 | <0·01
Parkinson's | Various | Apomorphine | 54 | 156 | 1298/1445 | 0·61 (0·49, 0·73) | 1·02 (0·73, 1·30) | [NAME] (-0·19, 1·46) | 80 (77-82) [<0·01] | <0·01 | 63 | 30·3 | <0·01 | 66·8 | NP | 32·2 | <0·01
Parkinson's | Various | Ciladopa (AY27110) | 2 | 8 | 100/100 | [NAME] (-0·38, 0·38) | [-0·37 (-1·36, 0·62)] | 1·40 (0·55, 2·25) | 85 (71-91) [<0·01] | <0·01 | 5 | 0·4 | <0·01 | 1·08 | <0·01 | 6·84 | NP
Parkinson's | Disability rating | [NAME] | 5 | 9 | 45/45 | 3·14 (1·70, 4·58) | [NAME] (2·09, 6·85) | 1·94 (-0·70, 4·57) | 45 (0-73) [0·07] | <0·01 | 6 | 9 | NP | 9 | NP | 5·93 | 0·99
Parkinson's | Various | Bromocriptine | 36 | 79 | 436/490 | 0·96 (0·76, 1·17) | 0·95 (0·71, 1·18) | 0·97 (0·02, 1·91) | 15 (0-36) [0·14] | <0·01 | 15 | 19·7 | NP | 19·3 | NP | 19·8 | NP
Parkinson's | Various | Cabergoline | 6 | 14 | 91/91 | 0·55 (0·05, 1·06) | 0·78 (-0·18, 1·74) | [-0·23 (-1·63, 1·16)] | 69 (39-81) [<0·01] | 0·07 | 4 | 1·9 | 0·11 | 3·05 | 0·52 | 0·91 | 0·01
Parkinson's | Spontaneous activity | CY208-243 | 2 | 4 | 32/32 | 1·29 (0·43, 2·15) | 1·29 (0·43, 2·15) | 0·89 (-0·74, 2·52) | 0 (0-68) [0·87] | <0·01 | 0 | 2·4 | NP | 2·4 | NP | 1·32 | NP
Parkinson's | Various | Dihydrexidine | 9 | 17 | 67/67 | 0·57 (-0·05, 1·18) | 0·57 (-0·05, 1·18) | 0·37 (-1·62, 2·36) | 0 (0-45) [0·95] | 0·20 | 0 | 1·62 | NP | 1·62 | NP | 2·62 | NP
Parkinson's | Rotational behavior | Dinapsoline | 5 | 15 | 131/131 | 2·03 (1·59, 2·47) | 2·30 (1·48, 3·11) | 1·47  (0·07, 2·87) | 69 (41-81) [<0·01] | 0·13 | 10 | 14 | NP | 14·3 | NP | 11·2 | NP
Parkinson's | Rotational behavior | Dopamine | 1 | 3 | 15/15 | 1·19 (-0·08, 2·46) | 1·30 (-0·23, 2·82) | 0·72 (-1·13, 2·58) | 24 (0-79) [0·27] | 0·04 | 1 | 0·91 | 0·99 | 1·04 | NP | 0·45 | 0·38
Parkinson's | Various | Lisuride | 10 | 15 | 100/146 | 1·39 (0·99, 1·80) | 1·39 (0·99, 1·80) | 1·04 (0·18, 1·90) | 0 (0-46) [0·55] | 0·18 | 7 | 6·85 | 0·99 | 6·85 | 0·99 | 4·62 | 0·26
Parkinson's | Various | LY-171555 | 13 | 37 | 196/194 | 0·14 (-0·16, 0·43) | 0·35 (-0·07, 0·78) | [-0·38 (-1·42, 0·66)] | 42 (7-60) [<0·01] | <0·01 | 3 | 2 | 0·45 | 2·85 | 0·76 | 3·01 | NP
Parkinson's | Various | Pergolide | 8 | 14 | 126/123 | 0·67 (0·30, 1·03) | 1·01 (0·26, 1·76) | 0·32 (-0·47, 1·12) | 69 (38-81) [<0·01] | <0·01 | 4 | 3·25 | 0·75 | 5·99 | NP | 1·3 | 0·03
Parkinson's | Various | Piribedil | 12 | 42 | 194/206 | 1·09 (0·75, 1·43) | 1·41 (0·85, 1·97) | 0·09 (-0·89, 1·07) | 55 (33-68) [<0·01] | <0·01 | 5 | 10·4 | NP | 15·2 | NP | 2·17 | 0·06
Parkinson's | Various | Pramipexole | 8 | 16 | 146/143 | 1·42 (0·97, 1·87) | 1·43 (0·83, 2·03) | 1·81 (0·45, 3·16) | 40 (0-66) [0·05] | 0·76 | 6 | 11·4 | NP | 11·4 | NP | 13·7 | NP
Parkinson's | Various | Quinelorane | 5 | 5 | 24/21 | 1·06 (0·15, 1·97) | 1·22 (-0·43, 2·86) | 2·48 (0·88, 4·07) | 65 (0-85) [0·02] | 0·43 | 2 | 1·11 | 0·31 | 1·35 | 0·62 | 3·75 | NP
Parkinson's | Various | Quinpirole | 22 | 43 | 320/312 | 1·09 (0·87, 1·31) | 1·08 (0·65, 1·50) | 1·47 (0·77, 2·17) | 67 (53-75) [<0·01] | 0·94 | 14 | 17 | NP | 16·7 | NP | 25·2 | NP
Parkinson's | Various | Ropinirole | 13 | 33 | 165/165 | 1·85 (1·39, 2·32) | 1·85 (1·39, 2·32) | [NAME] (-0·81, 2·07) | 0 (0-35) [0·75] | 0·37 | 9 | 19·1 | NP | 19·1 | NP | 4·22 | 0·03
Parkinson's | Various | Rotigotine | 1 | 13 | 75/83 | 1·76 (1·21, 2·32) | 1·76 (1·21, 2·32) | 1·81 (0·88, 2·74) | 0 (0-49) [0·44] | 0·15 | 3 | 6·65 | NP | 6·65 | NP | 6·84 | NP
Parkinson's | Spontaneous activity | RU24213 | 3 | 6 | 78/108 | 0·77 (0·29, 1·26) | 0·82 (0·17, 1·48) | 0·29 (-0·81, 1·38) | 45 (0-76) [0·11] | 0·01 | 2 | 2·9 | NP | 3·2 | NP | 0·67 | 0·14
Parkinson's | Rotational behavior | S31411 | 2 | 3 | 15/15 | 0·98 (-0·13, 2·10) | 0·98 (-0·13, 2·10) | 0·89 (-1·02, 2·79) | 0 (0-73) [0·99] | 0·02 | 0 | 0·69 | NP | 0·69 | NP | 0·59 | NP
Parkinson's | Various | S32504 | 15 | 36 | 290/290 | 0·93 (0·62, 1·23) | 0·97 (0·35, 1·60) | 0·23 (-0·91, 1·36) | 75 (64-81) [<0·01] | 0·63 | 14 | 12·7 | 0·73 | 13·7 | 0·99 | 2·5 | <0·01
Parkinson's | Rotational behavior | [NAME] | 1 | 2 | 10/10 | 0·13 (-0·95, 1·21) | 0·13 (-0·95, 1·21) | 0·03 (-1·49, 1·54) | 0 (ΝΑ) [0·85] | ΝΑ | 0 | 0·11 | NP | 0·11 | NP | 0·1 | NP
Parkinson's | Various | S33084 | 2 | 2 | 12/12 | 0·72 (-0·13, 1·56) | 0·72 (-0·13, 1·56) | 0·38 (-0·76, 1·53) | 0 (NA) [0·40] | ΝΑ | 0 | 0·35 | NP | 0·35 | NP | 0·17 | NP
Parkinson's | Various | Sarizotan | 8 | 12 | 60/60 | [-0·13 (-0·66, 0·40)] | [-0·13 (-0·66, 0·40)] | 0 (-1·75, 1·75) | 0 (0-50) [0·86] | 0·02 | 0 | 0·64 | NP | 0·64 | NP | 0·6 | NP
Parkinson's | Various | SKF 83959 | 3 | 4 | 18/18 | 1·11 (0·29, 1·94) | 1·51 (-0·03, 3·05) | 0·53 (-0·91, 1·96) | 67 (0-86) [0·03] | 0·04 | 2 | 0·96 | 0·25 | 1·53 | 0·64 | 0·39 | 0·05
Parkinson's | Rotational behavior | SKF 104557 | 1 | 2 | 8/16 | 0·10 (-2·73, 2·93) | 0·10 (-2·73, 2·93) | [-0·01 ([NAME], 2·87)] | 0 (NA) [0·67] | NA | 0 | 0·1 | NP | 0·1 | NP | 0·1 | NP
Parkinson's | Various | SKF 38393 | 14 | 38 | 324/362 | 0·49 (0·25, 0·72) | 0·38 (-0·10, 0·85) | 0·53 (-0·40, 1·46) | 72 (61-79) [<0·01] | 0·17 | 12 | 5·62 | <0·01 | 4·13 | <0·01 | 6·33 | 0·03
Parkinson's | Various | SKF 80723 | 2 | 2 | 10/10 | 3·04 (1·42, 4·67) | 4·04 ([NAME], 8·09) | 2·30 (0·51, 4·09) | 73 (NA) [0·05] | NA | 2 | 2 | 0·99 | 2 | 0·99 | 1·69 | 0·99
Parkinson's | Various | SKF 81297 | 11 | 26 | 127/123 | 0·55 (0·20, 0·89) | 0·55 (0·20, 0·89) | 0·21 (-0·46, 0·89) | 0 (0-38) [0·99] | 0·02 | 1 | 2·77 | NP | 2·77 | NP | 1·52 | NP
Parkinson's | Various | SKF 82958 | 10 | 16 | 93/95 | 1·16 (0·80, 1·53) | 1·39 (0·80, 1·99) | 0·58 (-0·43, 1·59) | 57 (13-74) [<0·01] | 0·03 | 7 | 5·73 | 0·6 | 7·53 | NP | 2·12 | <0·01
Parkinson's | Rotational behavior | SKF 89124 | 1 | 4 | 16/32 | 0·68 (-2·54, 3·90) | 0·68 (-2·54, 3·90) | 0·38 (-2·98, 3·74) | 0 (0-68) [0·94] | <0·01 | 0 | 0·6 | NP | 0·6 | NP | 0·33 | NP
Parkinson's | Rotational behavior | SKF 96990 | 2 | 3 | 12/24 | [NAME] (-1·81,1·77) | [[NAME] (-1·81, 1·77)] | [-0·17 (-3·15, 2·81)] | 0 (0-73) [0·96] | 0·05 | 0 | 0·15 | NP | 0·15 | NP | 0·17 | NP
Parkinson's | Rotational beha | SKF 97930 | 1 | 2 | 8/16 | 0·09 (-2·33, 2·51) | 0·09 (-2·33, 2·51) | [-0·21 (-3·24, 2·82)] | 0 (NA) [0·75] | NA | 0 | 0·1 | NP | 0·1 | NP | 0·12 | NP
Parkinson's | Various | SLV308 | 3 | 10 | 40/40 | 1·14 (0·04, 2·25) | 1·14 (0·04, 2·25) | 0·29 (-2·15, 2·73) | 0 (0-53) [0·84] | <0·01 | 0 | 2·16 | NP | 2·16 | NP | 0·62 | NP
Parkinson's | Various | Sumanirole | 2 | 8 | 33/33 | 1·64 (0·71, 2·57) | 1·70 (0·15, 3·25) | 0·53 (-1·53, 2·59) | 59 (0-79) [0·02] | 0·51 | 2 | 2·92 | NP | 3·07 | NP | 0·74 | 0·16
Parkinson's | Various | Talipexole | 15 | 41 | 239/238 | 0·79 (0·51, 1·07) | 0·86 (0·45, 1·27) | 1·03 (0·33, 1·73) | 40 (5-58) [<0·01] | 0·02 | 9 | 8·06 | 0·69 | 9·1 | NP | 11·8 | NP
Parkinson's | Various | Terguride | 6 | 8 | 54/54 | 0·80 (0·22, 1·37) | 0·80 (0·22, 1·37) | 0·21 (-1·03, 1·45) | 0 (0-56) [0·58] | 0·02 | 0 | 1·86 | NP | 1·86 | NP | 0·5 | NP
SCI | Neurobe-Motor | Stem cells | 89 | 186 | 2023/1934 | 0·96 (0·87, 1·04) | 1·13 (0·97, 1·29) | 0·28 (-0·39, 0·94) | 70 (65-74) [<0·01] | <0·01 | 85 | 85·8 | NP | 107 | NP | 16·5 | <0·01
SCI | Neurobe-Sensory | Stem cells | 8 | 22 | 251/190 | 0·59 (0·33, 0·86) | 0·47 (0·01, 0·92) | 0·65 (-0·13, 1·42) | 63 (37-76) [<0·01] | 0·12 | 5 | 4·5 | 0·79 | 3·2 | 0·36 | 5·1 | NP
Abbreviations: EAE, experimental autoimmune encephalomyelitis; ICH, intracerebral hemorrhage; Focal, focal ischemia; SCI, spinal cord injury; NP, not pertinent, because the estimated E is larger than the O, and there is no evidence of excess statistical significance based on the assumption made for the plausible effect size; PPAR, peroxisome proliferator-activated receptor; ORF4-PE, antisense oligodeoxynucleotides;  [NAME], a thyrotropin releasing hormone derivative; PHNO, a dopamine D2 receptor agonist; 7-OH-DPAT, a dopamine D3 receptor agonist; A68930/A77636/A86929/ABT431/BAM-1110/CY208-243/LY-171555/RU-24213/S31411/S32504/S32601/S33084/SLV308, dopamine receptor agonists; SKF83959/SKF104557/SKF38393/SKF80723/SKF81297/SKF82958/SKF89124/SKF96990/SKF97930, benzazepine dopamine agonists·
* Summary random effects odds ratio (95% CI) of each meta-analysis
† Summary fixed effects odds ratio (95% CI) of each meta-analysis
‡ Odds ratio (95% CI) of the most precise study in each meta-analysis
§ P-value from the Egger regression asymmetry test for evaluation of publication bias, except for six meta-analyses (Wang, 2007; [NAME], 2008; [NAME], 2009; Hobbs, 2006 [oropharynx CA]; [NAME], 2005; [NAME], 1998 [HCV-]) where P-values are from the [NAME] modified regression test
|| I2 metric of inconsistency (95% confidence intervals of I2) and P-value of the Cochran Q test for evaluation of heterogeneity
¶ Observed number of statistically significant studies
# Expected number of statistically significant studies using the summary fixed effects estimate of each meta-analysis as the plausible effect size
** P-value of the excess statistical significane test
†† Expected number of statistically significant studies using the summary random effects estimate of each meta-analysis as the plausible effect size
‡‡ Expected number of statistically significant studies using the effect of the most precise study of each meta-analysis as the plausible effect size